🐾 Apoquel tablets 16 mg, 20 pcs.

Apoquel belongs to the group of selective Janus Kinase Inhibitors (JAK) drugs.

Oclacitinib maleate, a component of the drug, inhibits the functions of proinflammatory, proallergic and pruritogenic (pruritogenic) cytokines dependent on the enzymatic activity of Janus Kinase JAK1 or JAK3 at therapeutic dose, the targeted effect on which allows inhibiting key mechanisms of allergy-related itching and helps to eliminate the symptoms of local inflammation; cytokines involved in hematopoiesis and dependent on JAK2 are not significantly affected.

After oral administration oclacytinib maleate is quickly absorbed in gastro-intestinal tract (bioavailability is 89 %), enters systemic blood flow, maximum concentration in plasma is reached in less than 1 hour, penetrates into most organs and tissues, is practically not metabolized, excreted unchanged, mainly with urine, elimination half-life is 3-4 hours.

Apokvel is classified as moderately hazardous substances (3 class of hazard according to GOST 12.1.007) with weakly expressed cumulative properties; in recommended dose it does not exhibit mutagenic, carcinogenic, embryotoxic and teratogenic activity.

Special instructions

Empty drug bottles must not be used for household purposes; they must be disposed of with household waste.
Features of the action during the first use of the drug and upon its withdrawal have not been identified.
Omissions should be avoided when administering the next dose of the drug, as this may lead to a decrease in effectiveness. If the next dose is missed, the use of Apoquel is resumed in accordance with these instructions. Apoquel is not intended for use in food producing animals.

Side Effects

Side effects and complications with short-term use of Apoquel can manifest as depression, dysfunction of the gastrointestinal tract, cystitis; in animals receiving Apoquel for more than 16 days, in approximately 1% of cases, increased appetite and aggression, skin and subcutaneous neoplasms, skin infections caused by yeast, enlarged lymph nodes, exacerbation of demodicosis and cancer may be observed.

Contraindications

A contraindication to the use of Apoquel is the individual intolerance of the animal to its components.

The drug should not be used in dogs with signs of immunosuppression, such as hyperadrenocorticism, or in dogs with progressive malignant neoplasms.

The drug should not be used by male dogs during the mating period, dogs under 12 months of age and/or weighing less than 3 kg, as well as puppies and lactating bitches.

Active ingredient

Oclacitinib

Interaction

When Apoquel was used together with antimicrobial, anti-inflammatory and antiparasitic drugs, no pharmacological interaction was detected. Apoquel should not be used in combination with immunosuppressants and anticonvulsants.

Manufacturer

Zoetis, Italy

Shelf life

3 years from production date